Literature DB >> 26718856

Materials for non-viral intracellular delivery of messenger RNA therapeutics.

Kevin J Kauffman1, Matthew J Webber2, Daniel G Anderson3.   

Abstract

Though therapeutics based on messenger RNA (mRNA) have broad potential in applications such as protein replacement therapy, cancer immunotherapy, and genomic engineering, their effective intracellular delivery remains a challenge. A chemically diverse suite of delivery materials with origins as materials for cellular transfection of DNA and small interfering RNAs (siRNAs) has recently been reported to have promise as non-viral delivery agents for mRNA. These materials include covalent conjugates, protamine complexes, nanoparticles based on lipids or polymers, and hybrid formulations. This review will highlight the use of delivery materials for mRNA, with a specific focus on their mechanisms of action, routes of administration, and dosages. Additionally, strategies in which these materials can be adapted and optimized to address challenges specific to mRNA delivery are also discussed. The technologies included have shown varying promise for therapeutic use, specifically having been used to deliver mRNA in vivo or exhibiting characteristics that could make in vivo use a possibility. In so doing, it is the intention of this review to provide a comprehensive look at the progress and possibilities in applying nucleic acid delivery technology specifically toward the emerging area of mRNA therapeutics.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug delivery; Endosomal escape; Gene therapy; Genome editing; Immunoengineering; mRNA

Mesh:

Substances:

Year:  2015        PMID: 26718856     DOI: 10.1016/j.jconrel.2015.12.032

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  105 in total

Review 1.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 2.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 3.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 4.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

5.  Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals.

Authors:  Colin J McKinlay; Jessica R Vargas; Timothy R Blake; Jonathan W Hardy; Masamitsu Kanada; Christopher H Contag; Paul A Wender; Robert M Waymouth
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

6.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.

Authors:  Matthias A Oberli; Andreas M Reichmuth; J Robert Dorkin; Michael J Mitchell; Owen S Fenton; Ana Jaklenec; Daniel G Anderson; Robert Langer; Daniel Blankschtein
Journal:  Nano Lett       Date:  2016-12-05       Impact factor: 11.189

Review 7.  Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.

Authors:  Alvin J Mukalel; Rachel S Riley; Rui Zhang; Michael J Mitchell
Journal:  Cancer Lett       Date:  2019-05-14       Impact factor: 8.679

Review 8.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

Review 9.  Nanoscale platforms for messenger RNA delivery.

Authors:  Bin Li; Xinfu Zhang; Yizhou Dong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-05-04

10.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.